Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6501 to 6550 of 8905 results

  1. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development Reference number: GID-TA11277 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    Discontinued Reference number: GID-TA11252

    Technology appraisal guidance
    Discontinued

  3. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Discontinued Reference number: GID-TA11339

    Technology appraisal guidance
    Discontinued

  4. Benralizumab for previously treated severe nasal polyps [ID1659]

    In development Reference number: GID-TA10818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    Discontinued Reference number: GID-TA11109

    Technology appraisal guidance
    Discontinued

  6. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development Reference number: GID-TA11567 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued

  8. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  9. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  10. Breathlessness

    Discontinued Reference number: GID-NG10387

    NICE guideline
    Discontinued

  11. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  12. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  13. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  14. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  15. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued

  16. Preterm labour and birth - timing of cord clamping

    Discontinued Reference number: GID-NG10396

    NICE guideline
    Discontinued

  17. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued Reference number: GID-NG10394

    NICE guideline
    Discontinued

  18. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued Reference number: GID-NG10395

    NICE guideline
    Discontinued

  19. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

    NICE guideline
    Discontinued

  20. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

    Antimicrobial prescribing guideline
    Discontinued

  21. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  22. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  23. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

    Antimicrobial prescribing guideline
    Discontinued

  24. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  25. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

    Technology appraisal guidance
    Discontinued

  26. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    In development Reference number: GID-TA11128 Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development Reference number: GID-TA10899 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  29. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  30. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

    Medical technologies guidance
    In development

  33. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  37. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  38. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  40. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  41. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  42. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development Reference number: GID-TA11074 Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development Reference number: GID-TA11146 Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

    Technology appraisal guidance
    Discontinued

  49. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  50. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued